Citius Pharmaceuticals Inc (CTXR):企業の財務・戦略的SWOT分析

◆英語タイトル:Citius Pharmaceuticals Inc (CTXR) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH2501101FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Citius Pharmaceuticals Inc (Citius), formerly Trail One Inc is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care, and critical care drug products. The company’s proprietary product candidates include Mino-Lok, an antibiotic lock solution intended for the treatment of patients with catheter-related bloodstream infections, and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine intended to provide anti-inflammatory and anesthetic relief to patients suffering from Grade I and II hemorrhoids. Citius is headquartered in Cranford, New Jersey, the US

Citius Pharmaceuticals Inc Key Recent Developments

Mar 23,2021: Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok® at Benzinga Biotech Small Cap Conference on March 25
Feb 19,2021: 16:47 ET Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) (“Citius” or the “Company”), a specialty pharmaceutical company focused on de
Jan 25,2021: Citius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market
Jan 06,2021: Citius Pharmaceuticals to present update on proprietary product candidates at two virtual conferences in January

This comprehensive SWOT profile of Citius Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Citius Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Citius Pharmaceuticals Inc – Key Information
Citius Pharmaceuticals Inc – Overview
Citius Pharmaceuticals Inc – Key Employees
Citius Pharmaceuticals Inc – Key Employee Biographies
Citius Pharmaceuticals Inc – Key Operational Heads
Citius Pharmaceuticals Inc – Major Products and Services
Citius Pharmaceuticals Inc – History
Citius Pharmaceuticals Inc – Company Statement
Citius Pharmaceuticals Inc – Locations And Subsidiaries
Citius Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Citius Pharmaceuticals Inc – Business Description
Citius Pharmaceuticals Inc – Corporate Strategy
Citius Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Citius Pharmaceuticals Inc – Strengths
Citius Pharmaceuticals Inc – Weaknesses
Citius Pharmaceuticals Inc – Opportunities
Citius Pharmaceuticals Inc – Threats
Citius Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Citius Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Citius Pharmaceuticals Inc, Key Information
Citius Pharmaceuticals Inc, Key Ratios
Citius Pharmaceuticals Inc, Share Data
Citius Pharmaceuticals Inc, Major Products and Services
Citius Pharmaceuticals Inc, History
Citius Pharmaceuticals Inc, Key Employees
Citius Pharmaceuticals Inc, Key Employee Biographies
Citius Pharmaceuticals Inc, Key Operational Heads
Citius Pharmaceuticals Inc, Other Locations
Citius Pharmaceuticals Inc, Subsidiaries
Citius Pharmaceuticals Inc, Key Competitors
Citius Pharmaceuticals Inc, SWOT Analysis
Citius Pharmaceuticals Inc, Ratios based on current share price
Citius Pharmaceuticals Inc, Annual Ratios
Citius Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Citius Pharmaceuticals Inc (CTXR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • East-Central Iowa Rural Electric Cooperative:企業の発電所・SWOT分析2018
    East-Central Iowa Rural Electric Cooperative - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inf …
  • CSL Ltd (CSL):製薬・医療:M&Aディール及び事業提携情報
    Summary CSL Ltd (CSL) discovers, develops, manufactures, markets and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of bleeding disorders such as hemophilia and von Willebrand disease, hereditary angioedema, primary and second …
  • Camellia PLC (CAM):企業の財務・戦略的SWOT分析
    Summary Camellia Plc (Camellia) is a provider of business processing services. The company operates business through agriculture, food service, engineering and investment sectors. Camellia’s agriculture business division offers products such as rubber, maize, citrus, soya and barley, wine, pineapple …
  • Lear Corporation (LEA):企業の財務・戦略的SWOT分析
    Lear Corporation (LEA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • MDNA Life Sciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary MDNA Life Sciences Inc (MDNA) is a molecular diagnostics company that develops molecular tests based on the mitochondrial genome. The company’s prostate core mitomic test (PCMT) based on the science of mitochondrial DNA (mtDNA) is a tissue-based prostate cancer diagnostics for prostate and o …
  • Hansol Logistics Co., Ltd. (009180):企業の財務・戦略的SWOT分析
    Hansol Logistics Co., Ltd. (009180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Dorel Industries Inc.:企業の戦略・SWOT・財務情報
    Dorel Industries Inc. - Strategy, SWOT and Corporate Finance Report Summary Dorel Industries Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • LSK BioPartners Inc-製薬・医療分野:企業M&A・提携分析
    Summary LSK BioPartners Inc (LSK BioPartners) dba LSK BioPharma is a biopharmaceutical company which develops therapies for unmet medical needs in cancer. The company is developing proprietary drug candidate apatinib, a selective VEGFR-2 inhibitor for the treatment of solid tumor cancers such as met …
  • China Oriental Group Company Limited:企業の戦略・SWOT・財務情報
    China Oriental Group Company Limited - Strategy, SWOT and Corporate Finance Report Summary China Oriental Group Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • PepsiCo Inc:戦略・SWOT・企業財務分析
    PepsiCo Inc - Strategy, SWOT and Corporate Finance Report Summary PepsiCo Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Nephros Inc (NEPH):医療機器:M&Aディール及び事業提携情報
    Summary Nephros Inc (Nephros) is dialysis device manufacturer. The company offers infection control filters, dialysis ultrafilters, and hemodia filtration systems. Its dialysis ultrafilters includes Endotoxin ten Cartridge filter, SSUmini, DSU-D and SSU-D. Nephros dialysis ultrafilters are intended …
  • Evergreen Fibreboard Berhad:企業の戦略・SWOT・財務情報
    Evergreen Fibreboard Berhad - Strategy, SWOT and Corporate Finance Report Summary Evergreen Fibreboard Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • TauRx Pharmaceuticals Ltd:医療機器:M&Aディール及び事業提携情報
    Summary TauRx Pharmaceuticals Ltd (TauRx) discovers, develops and commercializes treatments and diagnostics for Alzheimer's disease and other neurodegenerative diseases. Its pipeline products include LMTX, a tau aggregation inhibitor (TAI) for Alzheimer’s and Behavioural variant frontotemporal demen …
  • The Northwestern Mutual Life Insurance Company:企業の戦略・SWOT・財務情報
    The Northwestern Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary The Northwestern Mutual Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • Voith Hydro Holding GmbH & Co KG:企業の戦略的SWOT分析
    Voith Hydro Holding GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • IntriCon Corp (IIN)-医療機器分野:企業M&A・提携分析
    Summary IntriCon Corp (IntriCon) is a designer, developer and manufacturer of miniature and micro-miniature body-worn medical and electronics products. The company’s products include glucose monitoring, medical coils, cardiac monitoring, amplifiers, systems, plastic medical molding, support products …
  • Olmuksan International Paper Ambalaj Sanayi ve Ticaret A.S.:企業の戦略・SWOT・財務情報
    Olmuksan International Paper Ambalaj Sanayi ve Ticaret A.S. - Strategy, SWOT and Corporate Finance Report Summary Olmuksan International Paper Ambalaj Sanayi ve Ticaret A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers th …
  • Shandong Weigao Group Medical Polymer Company Ltd (1066)-医療機器分野:企業M&A・提携分析
    Summary Shandong Weigao Group Medical Polymer Company Ltd (Weigao) researches, develops, manufactures and sells disposable medical consumables, orthopedic materials and blood purification products. Its products include infusion sets, needles, blood bags, heart eluting stents, blood sampling products …
  • Urigen Pharmaceuticals Inc:企業の戦略的SWOT分析
    Urigen Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Promentis Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Promentis Pharmaceuticals Inc (Promentis Pharmaceuticals) is a biopharmaceutical company that discovers and develops drugs for the treatment of schizophrenia and other central nervous system disorders. The company also develops therapies for neuropsychiatric disorders. It offers metabotropic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆